We are live on
!
Find out more
DCP
DSM Capital Partners Portfolio holdings
AUM
$5.66B
1-Year Est. Return
27.45%
This Fund
S&P 500
This Quarter
Est. Return
+12.3%
1 Year Est. Return
+27.45%
3 Year Est. Return
+126.04%
5 Year Est. Return
+156.94%
10 Year Est. Return
+722.36%
AUM
$6.74B
AUM Growth
+$615M
(+10%)
Cap. Flow
-$93.6M
Cap. Flow
% of AUM
-1.39%
Top 10 Holdings %
Top 10 Hldgs %
62.01%
Holding
48
New
9
Increased
14
Reduced
16
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$207M |
| 2 |
Microsoft
MSFT
|
+$188M |
| 3 |
COL
Rockwell Collins
COL
|
+$127M |
| 4 |
KSU
Kansas City Southern
KSU
|
+$119M |
| 5 |
Norwegian Cruise Line
NCLH
|
+$90M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$176M |
| 2 |
Affiliated Managers Group
AMG
|
+$139M |
| 3 |
Corpay
CPAY
|
+$117M |
| 4 |
Automatic Data Processing
ADP
|
+$105M |
| 5 |
AGN
Allergan plc
AGN
|
+$100M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Communication Services | 22.93% |
| 2 | Consumer Discretionary | 22.7% |
| 3 | Healthcare | 18.4% |
| 4 | Financials | 13.43% |
| 5 | Technology | 7.23% |
Similar funds
F
RMDI
AIM
O
AC
CRC
ACM
PI
DSM Capital Partners's Q2 2017 Portfolio in Review
As of Q2 2017, DSM Capital Partners held 48 positions worth $6.74B, up 10% from $6.13B the previous quarter. Its ten largest holdings account for 62% of the portfolio.
DSM Capital Partners's Q2 2017 filing shows 9 new, 14 increased, 16 reduced and 9 closed positions. Its largest new stake was Microsoft: 2,743,510 shares worth $189M. The largest sale was Celgene Corp, an estimated $176M.
By sector, the portfolio is most concentrated in Communication Services at 23% of assets, up from 22% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- DSM Capital Partners's largest Q2 2017 buy was Microsoft: 2,743,510 shares worth $189M.
- DSM Capital Partners added most to Regeneron Pharmaceuticals in Q2 2017, an estimated $207M increase.
- DSM Capital Partners's biggest Q2 2017 reduction was Allergan plc, cutting an estimated $100M.
- DSM Capital Partners fully exited Celgene Corp in Q2 2017, selling an estimated $176M.
- DSM Capital Partners's ten largest holdings make up 62% of its $6.74B portfolio in Q2 2017.
- DSM Capital Partners opened 9 new positions and closed 9 in Q2 2017.
- DSM Capital Partners's portfolio value rose 10% quarter-over-quarter to $6.74B.
Based on DSM Capital Partners's 13F filing for Q2 2017, filed 14 Aug 2017.